

## Duramycin Publications

1. Hu Y, Liu G, Zhang H, Li Y, Gray BD, Pak KY, Choi HS, Cheng D & Shi H. 2017. A Comparison of [<sup>99m</sup>Tc]duramycin and [<sup>99m</sup>Tc]Annexin V in SPECT/CT Imaging Atherosclerotic Plaques. **Molecular Imaging & Biology**. DOI:10.1007/s11307-017-1111-9.
2. Elvas F, Stroobants S, Wyffels L. 2017. Phosphatidylethanolamine targeting for cell death imaging in early treatment response evaluation and disease diagnosis. **Apoptosis** DOI 10.1007/s10495-017-1384-0
3. Elvas F, Boddart J, Vangestel C., Pak KY, Gray B, Kumar-Singh S, Staelens S, Stroobants S, Wyffels L. 2017. <sup>99m</sup>Tc-duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with F-18 FDG PET. **Journal of Nuclear Medicine** 58:665-670 as doi:10.2967/jnumed.116.182014
4. Liu Z, Larsen BT, Lerman LO, Gray BD, Barber C, Hedayat AF, Zhao M, Furenlid LR, Pak, KY, Woolfenden JM. 2016 *Detection of Atherosclerotic Plaques in ApoE-deficient Mice Using <sup>99m</sup>Tc-duramycin*. **Nuclear Medicine and Biology** 43:496-505.
5. Elvas F, Vangestel C., Pak K., Vermeulen P., Gray B., Stroobants S., Staelens S., Wyffels L. 2016 *Early prediction of tumor response to treatment: pre-clinical validation of <sup>99m</sup>Tc-duramycin*. **Journal of Nuclear Medicine**. 57:805-811.
6. Luo R, Niu L, Qiu F, Fang W, Fu T, Zhao M, Zhang YJ, Hua ZC, Li XF, Wang F. 2016. *Monitoring Apoptosis of breast Cancer Xenograft After Paclitaxel Treatment With <sup>99m</sup>Tc-Labeled Duramycin SPECT/CT*. **Mol Imaging**. Jan 29;15.
7. Medhora M, Haworth, Liu Y, Narayanan J, Gao F, Zhao M, Audi S, Jacobs E, Fish B, and Clough A. 2016. Biomarkers for Radiation Pneumonitis Using Noninvasive Molecular Imaging. **Journal of Nuclear Medicine** 2016; 57:1296–1301, DOI: 10.2967/jnumed.115.160291
8. Hou S, Johnson SE, Zhao M. 2015. *A One-Step Probe for Phosphatidylethanolamine*. **Chembiochem**. 16:1955-1960.
9. Elvas F, Vangestel C, Rapic S, Verhaeghe J, Gray BD, Pak KY, Stroobants S, Staelens S, Wyffels L. 2015. *Characterization of <sup>99m</sup>Tc Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis*. **Mol Imaging Biol**. DOI:10.1007/s11307-015-0852-6.
10. Wang L, Wang F, Fang W, Johnson SE, Audi S, Zimmer M, Holly TA, Lee DC, Zhu B, Zhu H, Zhao M. 2015. *The feasibility of imaging myocardial ischemic/reperfusion injury using <sup>99m</sup>Tc-labeled duramycin in a porcine model*. **Nuclear Medicine and Biology**. 42:198-204.
11. Ogawa K, Aoki M. 2014. *Radiolabeled Apoptosis Imaging Agents for Early Detection of Response to Therapy*. **ScientificWorldJournal**. ID 732603.
12. Audi SH, Jacobs ER, Zhao M, Roerig DL, Haworth ST, Clough AV. 2014 *In vivo detection of hyperoxia-induced pulmonary endothelial cell death using <sup>99m</sup>Tc-Duramycin*. **Nuclear Medicine and Biology**. 42:46-52.
13. Yao S, Hu K, Tang G, Liang X, Du K, Nie D, Jiang S, Zang L. 2014. *Positron emission tomography imaging of cell death with <sup>99m</sup>Tc-Duramycin*. **Apoptosis**. 19(5):841-50.
14. Johnson SE, Li Z, Liu Y, Moulder JE, Zhao M. 2013. *Whole-Body Imaging of high dose ionizing irradiation-induced tissue injuries using <sup>99m</sup>Tc-duramycin*. **Journal of Nuclear Medicine**. 54:1397-1403.
15. Zhang Y, Stevenson GD, Barber C, Furenlid LR, Barrett HH, Woolfenden JM, et al. 2013. *Imaging of rat cerebral ischemia-reperfusion injury using <sup>99m</sup>Tc-labeled duramycin*. **Nuclear Medicine and Biology**. 40 (1): 80-88.
16. Audi S, Li Z, Capacete J, Liu Y, Fang W, Shu LG, Zhao M. 2012. *Understanding the In Vivo Uptake Kinetics of a Phosphatidylethanolamine-binding Agent <sup>99m</sup>Tc-Duramycin*. **Nuclear Medicine and Biology**. 39:821-825.

17. Zhao M., Li Z. A single-step kit formulation for the  $^{99m}\text{Tc}$ -labeling of HYNIC-Duramycin. 2012. **Nuclear Medicine and Biology**. 39 (7):1006-11.
18. Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M. 2012. *Phosphatidylethanolamine is externalized at the surface of microparticles*. **Biochimica et biophysica acta**.1821(12):1501-7.
19. Stafford JH, Thorpe PE. 2011. *Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium*. **Neoplasia**.13(4):299-308.
20. Zhao M. *Lantibiotics as probes for phosphatidylethanolamine*. 2011 **Amino Acids**. 41(5):1071-9.
21. De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy FM.2009. *Molecular imaging of cell death*. **Methods**. (2):178-87.
22. Li Z, Wells CW, Esmon CT, Zhao M. 2009. *Phosphatidylethanolamine at the endothelial surface of aortic flow dividers*. **Journal of Thrombosis and Haemostasis**; 7(1):227-9.
23. Steiner I, Errhalt P, Kubesch K, Hubner M, Holy M, Bauer M, Müller M, Hinterberger S, Widmann R, Mascher D, Freissmuth M, Kneussl M. 2008. *Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers*. **Arch Pharmacol**. 378(3):323-33.
24. Marconescu A, Thorpe PE. 2008. *Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells*. **Biochim Biophys Acta**. 1778(10):2217-24.
25. Zhao M, Li Z, Bugenhagen S.  *$^{99m}\text{Tc}$ -labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe*. 2008. **Journal of Nuclear Medicine** 49(8):1345-1352.